This study expands the spectrum of <i>NTRK1</i> gene mutation associated with CIPA and provides a feasible approach for clinicians to treat patients with CIPA-related keratopathy. This evidence concerns the gene NTRK1 and hereditary sensory and autonomic neuropathy type 4.